Navigation Links
Lexicon Pharmaceuticals to Present at the RBC Healthcare Conference
Date:2/23/2012

THE WOODLANDS, Texas, Feb. 23, 2012 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that Arthur T. Sands, M.D., Ph.D., Lexicon's president and chief executive officer, will present at the RBC Healthcare Conference in New York on Tuesday, February 28, 2012, at 10:30 a.m. Eastern Time.  Dr. Sands will provide an overview on Lexicon's clinical development programs and milestones.

A live webcast of the presentation will be available through Lexicon's corporate website at www.lexpharma.com.  An archived version of the presentation will be available for 30 days after the event.

About Lexicon
Lexicon is a biopharmaceutical company focused on discovering breakthrough treatments for human disease.  Lexicon currently has four drug programs in mid-stage development for diabetes, irritable bowel syndrome, carcinoid syndrome and rheumatoid arthritis, all of which were discovered by Lexicon's research team.  Lexicon has used its proprietary gene knockout technology to identify more than 100 promising drug targets.  Lexicon has focused drug discovery efforts on these biologically-validated targets to create its extensive pipeline of clinical and preclinical programs.  For additional information about Lexicon and its programs, please visit www.lexpharma.com.

Safe Harbor Statement
This press release contains "forward-looking" statements, including statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information.  All forward-looking statements are based on
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
2. Lexicon Reports Initial Clinical Trial Results for LX1031, an Investigational New Drug for Irritable Bowel Syndrome
3. Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis
4. Lexicon Initiates Phase 2a Trial of LX6171 Drug Candidate for Cognitive Disorders
5. Lexicon Presents Clinical Data on LX1032 for Carcinoid Syndrome at European Neuroendocrine Tumor Society Meeting
6. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 First Quarter Results
7. Lexicons Drug Candidate LX1032 for Carcinoid Syndrome Receives Orphan Drug Designation From EMEA
8. Lexicon Completes Phase 1 Clinical Trial and Initiates Phase 2 Clinical Trial of LX4211 in Patients With Type 2 Diabetes
9. Lexicon Announces Pricing of Common Stock in Public Offering
10. Lexicon Announces Completion of Public Offering of Common Stock
11. Lexicon Pharmaceuticals to Present at the 12th Annual BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... QPID Health , a leader in clinical intelligence software, today ... and their first West Coast location in San ... in Boston , and will house product development, ... Southern California office will be located at 1000 ... demands of customers nationwide.  Both new locations will be operational ...
(Date:9/16/2014)... 16, 2014   Evana Automation Specialists , a ... and test systems, recently received a contract to provide ... manufacturer. The Evana solution will help error-proof the process ... well as reduce labor. A catheter ... robotic assembly cell. The robot will pick the adapter, ...
(Date:9/16/2014)... ORLANDO, Fla. , Sept. 16, 2014   ... standard in the patient experience at hospitals. The myComfort™ ... , Vestagen,s active barrier fabric that is fluid repellant, ... shown to inhibit the growth of bacteria on the ... the role clothing plays in the chain of transmission. ...
Breaking Medicine Technology:QPID Health Announces Major Office Expansion in Boston and Opens Facility in San Diego 2Evana Automation to Supply Robotic Assembly Cell to Leading Medical Device Manufacturer 2Evana Automation to Supply Robotic Assembly Cell to Leading Medical Device Manufacturer 3New Vestagen Patient Garments Aim to Minimize Pathogen Transmission Inside Hospitals 2
... (OTC Bulletin Board: ACUR) (the "Company") today announced ... "Agreement"), with an,investor group comprised of Vivo Ventures ... L.P., GCE Holdings LLC and certain individual investors,(the ... Units ("Units") at a price of $1.08 per ...
... 20 Ranbaxy Pharmaceuticals Inc.,(RPI), a wholly owned ... RLL has received approval from the U.S. Food ... and,Acetaminophen Tablets USP, 7.5 mg/750 mg, 10 mg/500 ... The Office of Generic Drugs, U.S. Food and ...
Cached Medicine Technology:Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate 2Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate 3Ranbaxy Receives Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP 2
(Date:9/16/2014)... September 15, 2014 For patients with locally advanced ... ablative radiation (SABR) may be a promising treatment ... may not otherwise be an option, according to ... Radiation Oncology,s (ASTRO,s) 56th Annual Meeting. , Surgery ... with pancreatic ductal adenocarcinoma (PDA), the most common ...
(Date:9/16/2014)... Discussion abstracts to be presented at the ESMO 2014 ... 2014 at 12:00 (CEST) to give you a first ... medical oncology Congress, under the leading theme Precision Medicine ... where genuinely targeted therapy is now possible for an ... are all working towards a common goal --improved patient ...
(Date:9/16/2014)... 2014 Fresh shiitake mushrooms are ... potassium. They are second-most consumed mushroom worldwide, for ... healing and health properties. , In addition to ... stimulate and strengthen the immune system and fight ... including beta glucans . These medicinal properties ...
(Date:9/16/2014)... 16, 2014 Brightree® , ... and billing software solutions for the post-acute care ... latest release of Brightree HME , serving ... providers as well as home infusion pharmacies. The ... (PARs), electronic purchasing, document management and electronic eligibility ...
(Date:9/16/2014)... Transparency Market Research, a U.S. - based ... market is expected to report an approximate value of ... Market (By Product Type - Skin Whitening/ Lightening and ... Masks and Others (fade creams, pore strips and toners)- ... 2013 – 2019,’ is now available for sale on ...
Breaking Medicine News(10 mins):Health News:Chemotherapy and SABR consecutively may be promising treatment option for advanced pancreatic cancer 2Health News:Chemotherapy and SABR consecutively may be promising treatment option for advanced pancreatic cancer 3Health News:Chemotherapy and SABR consecutively may be promising treatment option for advanced pancreatic cancer 4Health News:ESMO 2014 Congress Preview 2Health News:As Fall Schedules Settle In, Block Stress-Related Illness with Your Own Shiitake Mushroom Log Kit from Lost Creek Mushroom Farm 2Health News:As Fall Schedules Settle In, Block Stress-Related Illness with Your Own Shiitake Mushroom Log Kit from Lost Creek Mushroom Farm 3Health News:Brightree Announces Availability of Latest Release 2Health News:Brightree Announces Availability of Latest Release 3Health News:Brightree Announces Availability of Latest Release 4Health News:Global Facial Care Market Will Report a CAGR of 6.9% between 2013 and 2019: Transparency Market Research 2Health News:Global Facial Care Market Will Report a CAGR of 6.9% between 2013 and 2019: Transparency Market Research 3
... syndrome, by which 15% of Americans were suffered, was ... help, there's often little left// to do but to ... gas, flatulence make their lives miserable, limiting some of ... most basic of treatments is lifestyle modification instead of ...
... whether if new drugs and technologies are cost effective or not//. ... ... But British Medical Journal doctors complained that NICE has carried ... NHS resources better. ,NICE has published about 86 sets of guidance and recommendations ...
... the students and junior medical doctors of the Medical ... Hospitals have decided to not to run the outpatient ... protesting doctors have however promised not to cause any ... run a ‘parallel OPD’s’ for the benefit of patents. ...
... The soft green substance inside the body of a lobster ... delicacy and by may others as a waste//, unhealthy product. ... warning-advising people against eating too much of lobster tomalley. ... innards that serve as a liver and pancreas for lobster, ...
... medicos strike in India, the government on Sunday night proposed ... quota in central educational institutes// but the students and doctors ... calling a bandh in Delhi on May 31. ... with Federal Minister Oscar Fernandes who followed it up with ...
... the quota issue has been put on the national agenda ... many other more pressing problems. // ,Sam Pitroda ... criterion for selecting students for institutions of higher education. But ... of Technology (IITs) is not feasible. Already, the existing IITs ...
Cached Medicine News:Health News:Silence Puts Comfort For Digestive Syndrome 2Health News:Agitating Doctors Call For Two Day Shut Down Of OPD’ 2Health News:Quota System: Diverting Attention From The Real Problem 2Health News:Quota System: Diverting Attention From The Real Problem 3Health News:Quota System: Diverting Attention From The Real Problem 4
... Battery Powered Orthopedic Systems., ,The PowerPro® ... to the Hall® Surgical line of powered ... the first and only software controlled battery ... is a full-function orthopedic power system specifically ...
... Brasseler USAs Large Bone Power System is ... new technological advancements. The truly innovative design ... pack, which is comprised of the battery, ... contains only mechanical components, which provides a ...
... is a type I collagen implant designed ... or loss of meniscus tissue, typically through ... purpose of the CMI is to assist ... a more vigorous lifestyle, while forestalling or ...
... OBIs proprietary PolyGraft® material technology which ... that is both biologically friendly and ... of polylactide-co-glycolide, calcium sulfate and polyglycolide ... fabricated into products such as granules, ...
Medicine Products: